Literature DB >> 22001180

The role of cystatin C in improving GFR estimation in the general population.

Bjørn Odvar Eriksen1, Ulla Dorte Mathisen, Toralf Melsom, Ole Christian Ingebretsen, Trond Geir Jenssen, Inger Njølstad, Marit Dahl Solbu, Ingrid Toft.   

Abstract

BACKGROUND: The equations used to estimate glomerular filtration rate (GFR) based on serum creatinine level are limited by their dependence on muscle mass. Although cystatin C level predicts clinical outcomes better than creatinine level in the general population, its role in estimating GFR in the reference range is unclear. Cystatin C level is not influenced by muscle mass, but by several other non-GFR determinants. We investigated whether regression models using cystatin C level alone or in combination with creatinine level in principle would improve GFR estimation in the general population compared with models using creatinine level alone. STUDY
DESIGN: Study of diagnostic accuracy. SETTING & PARTICIPANTS: A representative sample (n = 1,621; aged 50-62 years) of the general population in Tromsø, Norway, without coronary heart disease, stroke, diabetes mellitus, or kidney disease. Individuals had participated in the Renal Iohexol Clearance Survey (RENIS-T6), part of the sixth Tromsø Study. INDEX TEST: Performance of multiple linear and fractional polynomial regression models with plasma creatinine and/or cystatin C levels as independent variables and measured GFR as a dependent variable. REFERENCE TEST: Plasma iohexol clearance. OTHER MEASUREMENTS: Creatinine measured with an enzymatic method. Cystatin C measured with a particle-enhanced turbidimetric immunoassay.
RESULTS: In internal validation of models with cystatin C, creatinine, or both levels, percentages of GFR estimates within 10% of measured GFR were 61% (95% CI, 58%-63%), 62% (95% CI, 59%-64%), and 68% (95% CI, 65%-70%), respectively. Models with either cystatin C or creatinine level had very similar precision and ability to detect GFR <90 mL/min/1.73 m(2), whereas models based on both markers performed better. LIMITATIONS: Only middle-aged individuals of European ancestry were investigated. Lack of standardization between cystatin C assays. No external validation of regression models.
CONCLUSIONS: Models based on cystatin C alone are not superior to those based on creatinine, but models based on both markers can improve GFR estimation in the reference range.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001180     DOI: 10.1053/j.ajkd.2011.09.001

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  16 in total

1.  Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C.

Authors:  Hans Pottel; Pierre Delanaye; Elke Schaeffner; Laurence Dubourg; Bjørn Odvar Eriksen; Toralf Melsom; Edmund J Lamb; Andrew D Rule; Stephen T Turner; Richard J Glassock; Vandréa De Souza; Luciano Selistre; Karolien Goffin; Steven Pauwels; Christophe Mariat; Martin Flamant; Natalie Ebert
Journal:  Nephrol Dial Transplant       Date:  2017-03-01       Impact factor: 5.992

2.  GFR estimating equations: getting closer to the truth?

Authors:  Andrew D Rule; Richard J Glassock
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 8.237

3.  Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.

Authors:  Malte Lenders; Sima Canaan-Kühl; Johannes Krämer; Thomas Duning; Stefanie Reiermann; Claudia Sommer; Jörg Stypmann; Daniela Blaschke; Nurcan Üçeyler; Hans-Werner Hense; Stefan-Martin Brand; Christoph Wanner; Frank Weidemann; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

4.  Midlife Blood Pressure and Late-Life GFR and Albuminuria: An Elderly General Population Cohort.

Authors:  Lesley A Inker; Aghogho Okparavero; Hocine Tighiouart; Thor Aspelund; Margret B Andresdottir; Gudny Eiriksdottir; Tamara Harris; Lenore Launer; Hjalmfridur Nikulasdottir; Johanna Eyrun Sverrisdottir; Hrefna Gudmundsdottir; Farzad Noubary; Gary Mitchell; Runolfur Palsson; Olafur S Indridason; Vilmundur Gudnason; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2015-05-16       Impact factor: 8.860

5.  [Pharmacotherapy in patients suffering from chronic kidney disease].

Authors:  J T Kielstein; F Keller
Journal:  Internist (Berl)       Date:  2012-07       Impact factor: 0.743

Review 6.  Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.

Authors:  Sebastian Harder; Jochen Graff
Journal:  Eur J Clin Pharmacol       Date:  2013-04-26       Impact factor: 2.953

7.  Novel filtration markers as predictors of all-cause and cardiovascular mortality in US adults.

Authors:  Meredith C Foster; Lesley A Inker; Andrew S Levey; Elizabeth Selvin; John Eckfeldt; Stephen P Juraschek; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2013-03-19       Impact factor: 8.860

8.  25-Hydroxyvitamin D levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and Lifestyle) study.

Authors:  Matthew J Damasiewicz; Dianna J Magliano; Robin M Daly; Claudia Gagnon; Zhong X Lu; Peter R Ebeling; Steven J Chadban; Robert C Atkins; Peter G Kerr; Jonathan E Shaw; Kevan R Polkinghorne
Journal:  BMC Nephrol       Date:  2012-07-03       Impact factor: 2.388

9.  Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C.

Authors:  George J Schwartz; Michael F Schneider; Paula S Maier; Marva Moxey-Mims; Vikas R Dharnidharka; Bradley A Warady; Susan L Furth; Alvaro Muñoz
Journal:  Kidney Int       Date:  2012-08       Impact factor: 10.612

10.  The urine microRNA profile may help monitor post-transplant renal graft function.

Authors:  Daniel G Maluf; Catherine I Dumur; Jihee L Suh; Mariano J Scian; Anne L King; Helen Cathro; Jae K Lee; Ricardo C Gehrau; Kenneth L Brayman; Lorenzo Gallon; Valeria R Mas
Journal:  Kidney Int       Date:  2013-09-11       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.